Rhenman & Partners Asset Management AB as of March 31, 2016
Portfolio Holdings for Rhenman & Partners Asset Management AB
Rhenman & Partners Asset Management AB holds 92 positions in its portfolio as reported in the March 2016 quarterly 13F filing
Company (Ticker) |
Portfolio Weight |
Valued At |
Change in Shares |
Share Count |
Share Price |
---|---|---|---|---|---|
Alexion Pharmaceuticals | 3.3 | $17M | 121k | 139.22 | |
Gilead Sciences (GILD) | 3.3 | $17M | 180k | 91.86 | |
BioMarin Pharmaceutical (BMRN) | 3.1 | $16M | 190k | 82.48 | |
Eli Lilly & Co. (LLY) | 2.8 | $14M | 195k | 72.01 | |
Pfizer (PFE) | 2.8 | $14M | 475k | 29.64 | |
Alkermes (ALKS) | 2.8 | $14M | 405k | 34.19 | |
Incyte Corporation (INCY) | 2.5 | $12M | 170k | 72.47 | |
Celgene Corporation | 2.4 | $12M | 120k | 100.09 | |
Abiomed | 2.4 | $12M | 125k | 94.81 | |
Allergan | 2.2 | $11M | 42k | 268.02 | |
CVS Caremark Corporation (CVS) | 2.2 | $11M | 105k | 103.73 | |
Medtronic (MDT) | 2.0 | $10M | 137k | 75.00 | |
St. Jude Medical | 2.0 | $9.9M | 180k | 55.00 | |
Biogen Idec (BIIB) | 2.0 | $9.9M | 38k | 260.32 | |
Zimmer Holdings (ZBH) | 1.9 | $9.7M | 91k | 106.63 | |
CIGNA Corporation | 1.9 | $9.5M | 69k | 137.25 | |
Bristol Myers Squibb (BMY) | 1.8 | $9.1M | 142k | 63.88 | |
Laboratory Corp. of America Holdings | 1.7 | $8.8M | 75k | 117.13 | |
Centene Corporation (CNC) | 1.7 | $8.7M | 142k | 61.57 | |
Medivation | 1.7 | $8.6M | 187k | 45.98 | |
Walgreen Boots Alliance (WBA) | 1.7 | $8.4M | 100k | 84.24 | |
Hca Holdings (HCA) | 1.6 | $8.1M | 104k | 78.05 | |
Alnylam Pharmaceuticals (ALNY) | 1.6 | $7.8M | 125k | 62.77 | |
Perrigo Company (PRGO) | 1.6 | $7.8M | 61k | 127.93 | |
UnitedHealth (UNH) | 1.5 | $7.7M | 60k | 128.90 | |
Cardinal Health (CAH) | 1.5 | $7.5M | 92k | 81.95 | |
Aetna | 1.5 | $7.5M | 67k | 112.34 | |
Abbvie (ABBV) | 1.5 | $7.4M | 130k | 57.12 | |
Express Scripts Holding | 1.4 | $7.3M | 106k | 68.69 | |
Endo International | 1.4 | $7.3M | 260k | 28.15 | |
Nektar Therapeutics (NKTR) | 1.4 | $7.2M | 525k | 13.75 | |
Amgen (AMGN) | 1.3 | $6.7M | 45k | 149.93 | |
Anthem (ELV) | 1.3 | $6.5M | 47k | 139.00 | |
McKesson Corporation (MCK) | 1.2 | $6.3M | 40k | 157.25 | |
Vertex Pharmaceuticals Incorporated (VRTX) | 1.2 | $6.2M | 78k | 79.49 | |
Cooper Companies | 1.2 | $6.2M | 40k | 153.98 | |
AmerisourceBergen (COR) | 1.1 | $5.5M | 63k | 86.56 | |
Dex (DXCM) | 1.0 | $5.1M | 75k | 67.91 | |
Cepheid | 1.0 | $5.0M | 150k | 33.36 | |
Humana (HUM) | 1.0 | $4.9M | 27k | 182.96 | |
Edwards Lifesciences (EW) | 1.0 | $4.9M | 55k | 88.22 | |
Cerner Corporation | 0.9 | $4.6M | 86k | 52.97 | |
Keryx Biopharmaceuticals | 0.9 | $4.4M | 950k | 4.67 | |
Regeneron Pharmaceuticals (REGN) | 0.9 | $4.3M | 12k | 360.42 | |
Zeltiq Aesthetics | 0.9 | $4.3M | 160k | 27.16 | |
Community Health Systems (CYH) | 0.8 | $4.2M | 225k | 18.51 | |
Supernus Pharmaceuticals (SUPN) | 0.8 | $4.1M | 270k | 15.25 | |
Halozyme Therapeutics (HALO) | 0.8 | $4.1M | 431k | 9.47 | |
Jazz Pharmaceuticals (JAZZ) | 0.8 | $3.9M | 30k | 130.57 | |
Ariad Pharmaceuticals | 0.8 | $3.8M | 600k | 6.39 | |
Becton, Dickinson and (BDX) | 0.8 | $3.8M | 25k | 151.84 | |
Livanova Plc Ord (LIVN) | 0.8 | $3.8M | 70k | 53.99 | |
Endologix | 0.7 | $3.6M | 435k | 8.36 | |
Radius Health | 0.7 | $3.3M | 105k | 31.44 | |
Horizon Pharma | 0.7 | $3.3M | 200k | 16.57 | |
Intra Cellular Therapies (ITCI) | 0.6 | $3.2M | 115k | 27.80 | |
HeartWare International | 0.6 | $3.1M | 100k | 31.42 | |
Omnicell (OMCL) | 0.6 | $3.1M | 110k | 27.87 | |
Lion Biotechnologies | 0.6 | $3.0M | 600k | 5.08 | |
Cempra | 0.6 | $3.0M | 171k | 17.52 | |
Revance Therapeutics (RVNC) | 0.6 | $3.0M | 170k | 17.46 | |
Dynavax Technologies (DVAX) | 0.6 | $2.9M | 150k | 19.24 | |
Insulet Corporation (PODD) | 0.5 | $2.7M | 82k | 33.16 | |
Xencor (XNCR) | 0.5 | $2.7M | 200k | 13.42 | |
Exelixis (EXEL) | 0.5 | $2.6M | 650k | 4.00 | |
Chimerix (CMRX) | 0.5 | $2.6M | 500k | 5.11 | |
Ionis Pharmaceuticals (IONS) | 0.5 | $2.6M | 64k | 40.50 | |
Esperion Therapeutics (ESPR) | 0.5 | $2.5M | 150k | 16.91 | |
Ultragenyx Pharmaceutical (RARE) | 0.5 | $2.5M | 40k | 63.30 | |
Fibrogen (FGEN) | 0.5 | $2.4M | 114k | 21.29 | |
Neurocrine Biosciences (NBIX) | 0.5 | $2.4M | 60k | 39.55 | |
Macrogenics (MGNX) | 0.5 | $2.3M | 120k | 18.75 | |
Portola Pharmaceuticals | 0.4 | $2.1M | 105k | 20.40 | |
Pacira Pharmaceuticals (PCRX) | 0.4 | $2.1M | 40k | 52.98 | |
Hologic (HOLX) | 0.4 | $2.1M | 60k | 34.50 | |
Achillion Pharmaceuticals | 0.4 | $2.1M | 266k | 7.72 | |
Tandem Diabetes Care | 0.4 | $1.8M | 209k | 8.71 | |
Rigel Pharmaceuticals | 0.3 | $1.8M | 850k | 2.08 | |
Catabasis Pharmaceuticals | 0.3 | $1.7M | 345k | 5.04 | |
Anthera Pharmaceutcls | 0.3 | $1.6M | 435k | 3.62 | |
ACADIA Pharmaceuticals (ACAD) | 0.3 | $1.4M | 50k | 27.96 | |
Regulus Therapeutics | 0.3 | $1.4M | 200k | 6.93 | |
Tetraphase Pharmaceuticals | 0.3 | $1.4M | 300k | 4.63 | |
Valeant Pharmaceuticals Int | 0.3 | $1.3M | 50k | 26.30 | |
Array BioPharma | 0.2 | $1.1M | 370k | 2.95 | |
Nevro (NVRO) | 0.2 | $1.1M | 20k | 56.25 | |
Mirati Therapeutics | 0.2 | $1.1M | 50k | 21.40 | |
Avalanche Biotechnologies In | 0.2 | $796k | 154k | 5.17 | |
Orexigen Therapeutics | 0.1 | $672k | 1.2M | 0.56 | |
Ocular Therapeutix (OCUL) | 0.1 | $386k | 40k | 9.65 | |
Bind Therapeutics | 0.1 | $294k | 134k | 2.20 | |
Threshold Pharmaceuticals | 0.0 | $93k | 202k | 0.46 |